Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification
Status:
Terminated
Trial end date:
2018-06-29
Target enrollment:
Participant gender:
Summary
[Study Design] This study is a single arm, multi-center phase II study of vistusertib
monotherapy in patients with relapsed small cell lung cancer (SCLC) harboring RICTOR
amplification. Patients will receive vistusertib monotherapy (50 mg BID per os every 12
hours) until they demonstrate objective disease progression or they meet any other
discontinuation criteria.
[Primary Objective] To investigate the efficacy of vistusertib monotherapy in patients with
relapsed SCLC patients harboring RICTOR amplification as 2nd or 3rd line therapy